Circulating Tumor DNA As Liquid Biopsy in Patients with Stage IV Solid Tumors, a Feasibility Study At MUSC HCC

Medical University of South Carolina (MUSC)

Status: Completed

Conditions: Solid Tumor, Adult

Treatments: Procedure: research blood draws

Study type: Observational

Funder types: Other

Identifiers

NCT03302325

102718

Details and patient eligibility

About

1. To demonstrate the ability to detect specific cancer mutations in ctDNA isolated from plasma of stage IV cancer patients at HCC.
2. To compare, in each patient, ctDNA longitudinal samples through treatment, and when available, with those of primary tumor and metastasis.

Full description

The overall goal of this study is to study circulating tumor DNA (ctDNA) in the blood to determine how cancer cells in patients react to treatment. DNA is short for deoxyribonucleic acid. DNA contains information that determines in part the traits, such as eye color, height, or disease risk, that are passed on from parent to child. This reaction will be measured by studying patient blood that will be collected before and during treatment until there is disease progression.

Enrollment: 20 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Confirmed diagnosis of stage IV malignancy, including any advanced solid tumors (including lymphoma)
• Eastern Cooperative Oncology Group (ECOG) performance Status (PS) 0-3
• Life expectancy ≥ 3 months
• Patients must be able to provide consent
• Patients can be enrolled in other interventional clinical trials

Exclusion criteria

• Age < 18-year-old

Trial design

20 participants in 1 patient group

Stage IV solid tumors

Description:

adult patients with stage IV cancer that are starting a new line of treatment

Treatment:

Procedure: research blood draws